| |
 |
Dr. Danny Soon, MBBS
Medical Director, D3 (Drug Discovery and Development), Agency for Science, Technology and Research (A*STAR)
Singapore |
|
| |
| Biography: |
|
| |
| Dr. Danny Soon is highly experienced clinical researcher specialising in early clinical phase drug development, having worked for 15 years at the Lilly-NUS Centre for Clinical Pharmacology (LNUS) through several roles. As the Managing Director and Principal Investigator for LNUS, Danny had responsibility and oversight for all clinical Phase 1 studies conducted and operations in the unit. Dr. Soon has been an investigator in over 90 clinical pharmacology studies, including first-in-human studies, biomarker development work, human physiology investigations and pivotal registration PK studies. |
| |
| Danny has recently joined D3, the drug development unit of the Singapore Agency for Science, Technology and Research (A*STAR), as Medical Director. In this role, he has oversight of the medical aspects of early phase clinical programmes for A*STAR as well as partnered assets. His current portfolio includes oncology and anti-infective medicines. |
| |
| Danny graduated with MBBS from NUS, and PG Dip in Drug Development Sciences from the University of Surrey. |
| |
| Session: |
|
| |
| 21st November 2015 (Saturday) |
 |
13:50 - 14:15 |
|
| |
| Session III: Early Clinical Development in Asia |
| Translational and Early Phase Clinical Research in Singapore |
| |
| |
| |
| |
| |
|
|
